Company Description
Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases.
The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease.
It operates in the United States. The company also advances additional cell replacement candidates targeting both sporadic and genetic forms of Parkinson's disease, as well as other candidates for conditions of the central nervous system (CNS).
Aspen Neuroscience, Inc. was formerly known as Aspen Biosciences, Inc. and changed its name to Aspen Neuroscience, Inc. in October 2018.
Aspen Neuroscience, Inc. was incorporated in 2018 and is based in San Diego, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 30, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 120 |
| CEO | Damien McDevitt |
Contact Details
Address: 10835 Road to the Cure, Suite 100 San Diego, California 92121 United States | |
| Phone | (858) 263-1222 |
| Website | aspenneuroscience.com |
Stock Details
| Ticker Symbol | ASPE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 2124080 |
| CUSIP Number | 044933109 |
| ISIN Number | US0449331091 |
| Employer ID | 83-1312969 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Damien McDevitt, Ph.D. | President, Chief Executive Officer and Director |
| Faheem Hasnain | Executive Chairman |
| Dalen Meeter | Chief Financial Officer |
| Lisa Johnson-Pratt, M.D. | Sasineprocel Development Lead and Chief Commercial Officer |
| Kim Raineri | Chief Technology Officer |
| Jeffrey Boerneke | General Counsel and Secretary |
| Thomas Daniel, M.D. | Director |
| Douglas Fisher, M.D. | Director |
| Cindy Perettie | Director |
| Caryn Peterson | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 3, 2026 | SCHEDULE 13G | Filing |
| Nov 2, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 2, 2026 | 8-K | Current Report |
| Oct 30, 2026 | 424B4 | Prospectus |
| Oct 29, 2026 | EFFECT | Notice of Effectiveness |
| Oct 29, 2026 | CERT | Certification by an exchange approving securities for listing |
| Oct 29, 2026 | 8-A12B | Registration of securities |
| Oct 26, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 22, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 9, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |